Company Filing History:
Years Active: 2017
Title: The Innovations of Qingpeng Zeng
Introduction
Qingpeng Zeng is a notable inventor based in Thousand Oaks, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological pathways.
Latest Patents
Zeng holds a patent for IRE-1α inhibitors, which are compounds designed to directly inhibit IRE-1α activity in vitro. These compounds, along with their prodrugs and pharmaceutically acceptable salts, are useful for treating diseases associated with the unfolded protein response. They can be utilized as single agents or in combination therapies, showcasing their versatility in medical applications.
Career Highlights
Zeng is currently associated with MannKind Corporation, where he continues to innovate and contribute to the advancement of therapeutic solutions. His work focuses on addressing critical health challenges through targeted drug development.
Collaborations
Zeng has collaborated with esteemed colleagues such as John Bruce Patterson and David Gregory Lonergan, enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Qingpeng Zeng's work exemplifies the intersection of innovation and healthcare, as he develops solutions that have the potential to improve patient outcomes. His contributions to the field are noteworthy and reflect a commitment to advancing medical science.